Drugs that can rectify amplifying pathways, e.g., Glucagon-like Peptide 1 (GLP-1) conjugates, could be useful in overriding β cell dysfunction and enhancing insulin secretion in T2D [26,27,28]. This evidence concerns the gene INS and type 2 diabetes mellitus.